|Over a week ago|
Science 37 backs 2022 revenue view $86M-$96M, consensus $91.13M » 06:0505/0905/09/22
Sees 2022 adjusted EBITDA…
Sees 2022 adjusted EBITDA ($65M)-($69M).
Science 37 reports Q1 EPS 35c, consensus (22c) » 06:0405/0905/09/22
Reports Q1 revenue…
Reports Q1 revenue $18.7M, consensus $15.06M. Q1 net income included a non-cash gain of $75.5M resulting from revaluation of the earn-out liability. Net bookings were $30.6M in Q1 vs. $40.7M for the same period in 2021. Net bookings for the quarter ended March 31, 2022 were negatively impacted by two large COVID study cancellations. "The first quarter of 2022 was marked by continued execution across all of our strategic priorities. We started the year with strong demand for our differentiated, end to end platform and revenue growth of 50% year over year. Additionally, we remained laser-focused on driving more cost out of the business," said CEO David Coman. "With our sales pipeline at an all-time high, several imminent new product introductions and rigid cost management, we anticipate that our current cash position is sufficient to support our plans to achieve long-term profitability."
|Over a month ago|
Science 37 appoints Shaalan Beg to Global Management Team » 07:5703/3103/31/22
Science 37 Holdings …
Science 37 Holdings nnounced it is adding Shaalan Beg, M.D., M.S.C.S. to its Global Management Team. Dr. Beg comes to Science 37 from the University of Texas, Southwestern Medical Center in Dallas, Texas where he served as Medical Director for the Clinical Research Office at the Simmons Comprehensive Cancer and held the position of Director Gastrointestinal Medical Oncology and Associate Professor of Hematology and Medical Oncology.
Fly Intel: Pre-market Movers » 08:5403/2203/22/22
BABA, JILL, GDS, RAIL, NKE, SCPH, EVAX, DAVE, OKTA, SNCE
Check out this morning's…
Science 37 sees CY21 revenue $86M-$92M, consensus $104.22M » 07:0403/2203/22/22
Science 37 is providing…
Science 37 is providing guidance for the calendar year ending December 31, 2022 for total revenues between $86 and $96 million.
Science 37 reports Q4 EPS (60c), consensus (21c) » 07:0403/2203/22/22
Reports Q4 revenue…
Reports Q4 revenue $20.4M, consensus $14.78M. "Our impressive financial performance in the fourth quarter and for the full year 2021 reflects our team's continued strong execution and commitment to expanding patient access and reach of our agile clinical trial offerings," said David Coman, Chief Executive Officer of Science 37. "As we look ahead to 2022, we expect a sustained market shift toward more decentralization and strong demand for our differentiated Operating System. We are on a clear pathway to growth and long-term profitability as we redefine the future of clinical research; and we are confident that we are well positioned to deliver on our objectives."
Science 37 publishes CNS therapeutic data from CNS survey » 07:5803/0103/01/22
Science 37 Holdings …
Science 37 Holdings published new CNS therapeutic data validating the growing trend toward decentralization as two-thirds of CNS survey respondents plan to execute an agile or decentralized clinical trial in 2022, an increase of more than 35 percent from last year. According to analysis, the CNS Research & Development spend will reach $32 billion USD by 2026, resulting in more than 4,000 clinical trials. To uncover these new trends in CNS clinical trials methodologies, Science 37 conducted a study of more than 70 clinical research executives, between December 2021 and January 2022. For CNS studies, survey respondents cited unexpected delays, data quality and limited patient populations among the key challenges for clinical trials, with effective patient recruitment as the single biggest challenge by more than 100% comparatively to the second challenge of endpoint collection. Being able to eliminate geographic barriers with agile and decentralized approaches and helping to ease patient burden can help alleviate these concerns and enable more efficient centralized enrollment into studies. The new data and insights also paint a vivid picture of the clinical trials landscape for the year ahead for CNS studies, suggesting significant increases in agile and decentralized approaches across numerous conditions-including major depressive disorder, Alzheimer's disease, and Parkinson's disease-and executed with a myriad of permutations of patient communities, mobile nursing, telemedicine investigators and connected devices - further demonstrating the need for a centralized Operating System with unified technology and centralized networks to effectively execute. Among the findings: Less than 60 percent of CNS respondents are planning to execute a traditional, site-based clinical trial in 2022, down from three in four for the previous year. Unexpected delays, data quality, and limited patient populations all ranked highly among the issues keeping respondents up at night, regarding CNS trials in general. Respondents cited the greatest single challenge of running an effective CNS study was patient recruitment by more than 100% comparatively to the second challenge of endpoint collection. Electronic clinical outcomes assessment and electronic patient-reported outcomes were cited as the most prevalent decentralized components in CNS, with two-thirds of CNS respondents planning to use these tools - showing the rising embrace of digital data collection and evidence generation. Among the largest-growing decentralized components of CNS studies cited were mobile nurses, up 40 percent and up 38 percent, respondents cited usage of Metasites or virtual sites that can enable more universal geographic coverage and access for patients. The three greatest perceived benefits of including agile and decentralized components in CNS clinical trials were increased patient retention, increased patient diversity and faster patient recruitment.
Science 37's Operating System receives ISO certification » 08:1502/2402/24/22
Science 37 Holdings, the…
Science 37 Holdings, the Agile Clinical Trial Operating System announced its Operating System has earned ISO 27001 certification for cybersecurity management as well as the ISO 27701:2019 privacy management certification extension. These two certifications demonstrate Science 37's continued commitment to embrace quality, robust cybersecurity, privacy and data protection rights.
|Over a quarter ago|
Science 37 says provider network grows sixfold in 2021 » 07:5602/1702/17/22
Science 37 Holdings…
Science 37 Holdings bolstered its centralized network of community providers by six times during the past year, contracting with more than 800 healthcare organizations and gaining access to nearly 28 million patients worldwide. Currently, less than three percent of physicians participate as clinical trial investigators, primarily due to infrastructure burdens that often serve as a deterrent - preventing more than 97 percent of providers from contributing to research. By expanding its network of community providers, Science 37 enables physicians-providers to present clinical research as a care option to their patients, without having to add expensive clinical research infrastructure.
Science 37, physIQ collaborate to enhance trial data from connected devices » 07:5702/0302/03/22
Science 37 Holdings…
Science 37 Holdings announced a collaboration to help research sponsors use remote biosensors and machine learning to build more robust data sets. This will help increase the number of digital biomarkers and generate insights from continuous data streams to more quickly and objectively demonstrate the safety and efficacy of treatments. physIQ's robust platform scalability, near real-time capabilities, established FDA clearance, and proven ability to support large global clinical trials strengthen Science 37's ability to support additional novel digital biomarkers, advance clinical events detection and provide more proactive safety monitoring. physIQ enables Sponsors to efficiently identify valuable digital measures from large amount of noise inherent in biosensors.